SOCIUM Inc.

Keio University to Collaborate with SOCIUM Inc. Strategic partnership aims to AI-driven drug discovery for Aging-Related Diseases

SOCIUM Inc. announced that SOCIUM Inc. (Head office: Chuo-ku, Tokyo, CEO: Dr. Hiroshi Kawai) has entered into a joint research agreement with Keio University (Motoshi Hayano, Assistant Professor, Department of Neuropsychiatry, Keio University School of Medicine, Department of Technology and Engineering, Keio University) regarding AI-driven Drug Discovery for Aging-Related Diseases.

About Joint Research:
Under the collaboration, Hayano Laboratory, Keio University, which has cutting-edge knowledge and disease models on aging-related diseases and SOCIUM Inc., which has its own AI-driven drug discovery platform Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™, will pursue the identification of novel anti-aging drugs which could not be found by conventional approach. SOCIUM Inc. will contribute to find unique gene expression patterns and MoA for aging-related disease by its analysis using the AI platform customized for aging-related diseases. Through this joint research, SOCIUM Inc. and Hayano Laboratory, Keio University will be able to identify novel drugs for aging-related diseases such as Alzheimer's disease and Sarcopenia, which are in high Unmet Medical Needs. SOCIUM Inc. and Hayano Laboratory, Keio University aim to create a healthy society with well-being.

About Hayano Laboratory, Department of Neuropsychiatry, Keio University School of Medicine, Department of Technology and Engineering, Keio University:
"Aging" is the most universal phenomenon in life, yet it is also the most diverse and complex. The acquisition of life span is a very important issue in understanding the evolution of life, and the elucidation of the characteristics and molecular mechanisms of aging is an important issue that will revolutionize our future social infrastructure. The laboratory is interested in the aging rate, timing, physical properties, and sensory organs among other aging characteristics. Currently the laboratory is focusing its research on aging-dependent organ dysfunction in the kidneys, joints, and bones, in

addition to diseases such as Alzheimer's, Parkinson's, depression and sarcopenia. Its goal is to understand the question of what is lifespan in organisms and how aging is controlled. The laboratory aims to develop biotech methods including small compound and gene therapeutics to rejuvenate aging.
Hayano Laboratory WEB: https://www.hayano-aging-lab.com/

About SOCIUM Inc.:
SOCIUM Inc. is the AI-powered, gene expression-inspired technology company pioneering the next generation of drug discovery. Its technology identifies new disease indications, especially rare diseases with high unmet needs that could be treated by your proprietary assets. The company also has an own development portfolio of over 23 diseases in the discovery stage, including oncology and rare diseases. The company is open to working with other pharmaceutical / biotech companies to expand the impact of their own pipeline assets.
Our research paper: https://socium.co.jp/achievements/

Media Inquiries
SOCIUM Inc.
AIST Tokyo Waterfront BIO-IT Research Building,
2-4-7, Aomi, Koto-ku, Tokyo 135-0064, JAPAN
Masaki Oka, Director, Corporate administrator
E-mail: contact@socium.co.jp
WEB: https://socium.co.jp/
TEL: +81(0)3-6869-7996